In the initial term of the agreement Metabolon will carry out small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules to end points of disease and gene mutations.
HLI cofounders are Dr J Craig Venter, Dr Robert Hariri and Dr Peter H Diamandis. Dr Venter, who is well known for leading Celera to the successful sequencing of the human genome, has been a member of Metabolon’s Scientific Advisory Board since 2003.
Under the agreement Metabolon will apply its leading metabolomics technology to augment the genetic and microbiome information HLI is collecting. Metabolon’s metabolomic approach identifies the full complement of metabolites present in a human biological specimen.
Metabolomics is important because quantifying and understanding the full picture of circulating biochemicals in the body can help researchers get a clearer picture of that individual’s health status, and provide markers and pathways associated with disease and drug action.
In addition, Metabolon will collaborate with HLI to identify small molecule biomarkers of disease, which Metabolon may then use to develop small molecule diagnostic tests.
Metabolon CEO Dr John Ryals noted the company is delighted to be aligned with HLI and the world-renowned scientific minds behind this new company.
"It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery," Dr Ryals added.